Prometheus Laboratories: PredictrPK ADA
Prometheus Laboratories this week launched the PredictrPK ADA test to help clinicians decide the proper dosage of adalimumab (AbbVie's Humira's) for adult Crohn's disease patients. The test uses serology markers, disease-specific variables, current dosing, ADA clearance, and a proprietary machine learning algorithm. According to San Diego-based Prometheus, PredictrPK ADA enables clinicians to quickly evaluate measured adalimumab and antibodies-to-adalimumab using the drug-tolerant homogeneous mobility shift assay technology at sample collection time. It also includes calculated adalimumab clearance.